QSI · Quantum-Si Inc
Market Cap
$182.61M
Shares
218.88M
Volume · Oct 5
19.19M
Avg daily vol (3M)
3.93M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.28
Open$1.53
Day$1.26–1.53
52W close$0.70–2.63
Avg vol 30d5.1M
Short int13.0M · 6.0% float · 10.3d
Short vol71%
Last earningsAug 13, 2026
DataNov 2020–Oct 2026
Filing10-Q · Aug 13
Up next
Next earnings call
Nov 16, 2026
Est · unconfirmed
· in 6 wks
filed Aug 13, 2026
call held Aug 13, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$1.60M
Trailing 12 months
Net income (TTM)
−$98.52M
Trailing 12 months
Revenue growth YoY
-41.8%
Year over year
Operating margin
-6,887.8%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+18.6%
Year over year · more shares
Price change (1Y)
+0.6%
Trailing year
Short interest
6.0%
Latest settlement · 10.3 days to cover
AI Brief
Q2 FY26 earnings call · Aug 13, 2026
Q2 FY26
TL;DR. Quantum-Si pushed the Proteus launch from end of 2026 to Q2 2027 to add an extra integrated instrument design cycle, announced a ~20% workforce reduction expected to deliver ~$12M in annualized savings, and extended its cash runway into Q4 2028 while reiterating 2026 guidance.
Bullish
- + Cash runway extended into Q4 2028 from Q2 2028 following cost actions
- + Management identifies a >$4B non-human proteomics market opportunity for Proteus
- + Strategic shift to application-oriented library prep kits expected to expand capabilities and reduce technical risk
- + Net loss narrowed to $23.5M in Q2 2026 from $28.8M in Q2 2025
Bearish
- − Proteus launch pushed from end of 2026 to Q2 2027 to add an extra instrument design cycle
- − Q2 2026 revenue fell 42% YoY to $344K as Platinum-to-Proteus transition dampens demand
- − Q2 2026 gross margin of 50% impacted by mix and transition-period commercial activity; H1 2026 gross margin was 41%
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.5 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+35%
above
Price vs 50-day avg
+57%
above
RSI (14)
67
neutral
MACD trend
Positive
52-week position
30%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+67%
trailing
6-month return
+52%
trailing
YTD return
+16%
this year
Relative strength
+41%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
-11% holders QoQ · +26 funds added
Insider flow
Distributing
Net -$39.4K over 90 days · 100% sells
Short interest
Falling
5.96% of float · ▼ -9.7% MoM · 10.3 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
141 holders — mid 3-yr range
Squeeze score
96
high risk · 0–100
Fundamentals
Revenue growth
−20%
Y/Y
Gross margin
47%
contracting
EPS growth
+28%
Y/Y
Free cash flow
$-97.2M
Quant / Vol
risk profile
Volatility
97%
annualized · 1-yr
Max drawdown
−73%
past year
ATR
9.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Aug 13, 2026
annual
Annual operating expense savings
$12M
full year 2026
Revenue
Initiated
$1M
prior FY $2.44M
midpoint −58.9% Y/Y
Adjusted operating expenses
Non-GAAP
Initiated
up to $98M
Total cash usage
Initiated
up to $93M
Guided vs delivered
· last 1 settled
Revenue
full year 2024
guided $3.7M – $4.2M
$3.06M
Miss −22.6%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+35%
Bullish
Price vs 50-day avg
+57%
Bullish
RSI (14)
67
Neutral
MACD trend
Positive
Bullish
52-week position
30%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
-11% holders QoQ · +26 funds added
Insider flow
Distributing
Net -$39.4K over 90 days · 100% sells
Short interest
Falling
5.96% of float · ▼ -9.7% MoM · 10.3 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
141 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $1 · 30%
Range high $3
vs 200-day avg +35%
vs 50-day avg +57%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | -41.22M | Six months ended June 30, 2026 | — |
| Adjusted total operating expenses non-GAAP | $43.9M | six months ended June 30, 2026 | — |
| EBITDA non-GAAP | -46.41M | Six months ended June 30, 2026 | — |
| Reduction in force | 20% | second quarter of 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
QSI
this stock
Quantum-Si Inc
|
$182.61M | +40.9% | -20.3% | — | 6.0% |
|
ABT
Abbott Laboratories
|
$174.90B | -20.1% | +5.7% | 28.1 | 1.1% |
|
MDT
Medtronic plc
|
$113.38B | -10.1% | +8.4% | 21.8 | 1.3% |
|
SYK
Stryker Corp
|
$104.47B | -21.6% | +11.2% | 28.2 | 2.0% |
|
BSX
Boston Scientific Corp
|
$63.59B | -55.3% | +12.5% | 17.8 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| QSI | +61.0% | +67.1% | +52.2% | +19.6% | +16.4% |
| SPY | +1.2% | +0.6% | +11.6% | +1.6% | +13.6% |
| vs SPY | +59.8% | +66.5% | +40.6% | +18.0% | +2.7% |